CYTAL · Application of recombinant lactic acid bacteria secreting Interleukine12 for enhancement of Th1 response and alleviation of allergic disease

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Common allergic disease has trebled in the last twenty years, resulting in approximately one-fifth of the EU population likely to be seeking treatment for allergy. Potentially life-threatening conditions such as peanut allergy now affect about one in 70 children and are still increasing.Asthma, rhinitis and eczema have increased two- to three-fold in the last twenty years. The cytokine IL12 is one of the most powerful Th1 lymphokines and it has been found to cure Th2 cytokine-mediated murine schistosomias is and to inhibit allergic airway responses in a mouse model of asthma. IL12 has also been shown to be involved in protection against bacterial and parasitic infection as well as displaying anti-tumour activity.The objective of this proposal is to engineer recombinant strains of the food grade bacterium Lactococcus lactis capable of secreting IL12 and to develop this as an alternative delivery vehicle for cytokine administration. We plan to use an existing allergy mouse model to test the effectiveness of the recombinant L.lactis in inducing IL12 response and alleviation of allergic disease.This is a multidisciplinary project which will provide the Marie Curie Fellow with research training in modern molecular genetics of lactic acid bacteria as well as complementary skills the use of animal mode, protein analysis, immunochemistry and cytokine analysis.

Original text from CORDIS.

Participants

• INSTITUTE OF FOOD RESEARCH · NORWICHCoordinatorCity levelUnited Kingdom

Links

• View on CORDIS